title: Inactivation of 4-oxalocrotonate tautomerase by 2-oxo-3-pentynoate.
abstract: The compound, 2-oxo-3-pentynoate, has been synthesized and tested as an inhibitor of the enzyme 4-oxalocrotonate tautomerase. The enzyme is rapidly and irreversibly inactivated by the acetylenic product analogue in a time-dependent fashion. The enzyme displays saturation kinetics and is protected from inactivation by the presence of substrate. These observations are consistent with inactivation taking place at the active site. Partial reactivation ( approximately 18%) occurs by incubating the inactivated enzyme with 10 mM hydroxylamine (pH 7.3). The partition ratio, determined to be approximately 0.4, suggests that the inactivation of 4-OT by 2-oxo-3-pentynoate shows half-of-the-sites stoichiometry. The same phenomenon is observed in the inactivation of 4-OT by 3-bromopyruvate and can be explained by examination of the crystal structure. Mass spectral analysis shows that a single residue is modified on the enzyme which has been localized to the nine residue amino-terminal fragment Pro-1 to Glu-9. It can be reasonably concluded that Pro-1 is the site of covalent attachment. Inactivation of 4-OT can occur by either a Michael addition of 4-OT to C-4 of 2-oxo-3-pentynoate or by the enzyme-catalyzed rearrangement of 2-oxo-3-pentynoate to an allene derivative which alkylates Pro-1. These results provide the foundation for the use of 2-oxo-3-pentynoate in future mechanistic studies and as a ligand in an inactivated 4-OT complex that can be studied by X-ray crystallography. Finally, 2-oxo-3-pentynoate is an acetylene analogue of a variety of 2-oxo acids and as such may have general utility as an inhibitor of reactions that bind and process these compounds.
authors.affiliation: Medicinal Chemistry Division, College of Pharmacy, The University of Texas, Austin, Texas 78712, USA.
authors.forename: W H
authors.initials: WH
authors.lastname: Johnson
authors.forename: R M
authors.initials: RM
authors.lastname: Czerwinski
authors.forename: M C
authors.initials: MC
authors.lastname: Fitzgerald
authors.forename: C P
authors.initials: CP
authors.lastname: Whitman
mesh_terms: D001665:Binding Sites; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D019811:Hydroxylamine / Q000494:pharmacology; D007535:Isomerases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D007700:Kinetics; D013058:Mass Spectrometry; D015394:Molecular Structure; D010446:Peptide Fragments / Q000032:analysis / Q000737:chemistry; D011485:Protein Binding; D016958:Pseudomonas putida / Q000201:enzymology; D011773:Pyruvates / Q000494:pharmacology
chemical_list: C109822:2-oxo-3-pentynoic acid; D004791:Enzyme Inhibitors; D005231:Fatty Acids, Unsaturated; D010446:Peptide Fragments; D011773:Pyruvates; D019811:Hydroxylamine; C017092:bromopyruvate; C021918:4-oxalocrotonate tautomerase; D007535:Isomerases